Valuation: Clarity Pharmaceuticals Ltd

Market Cap 660M 462M 411M 381M 346M 649M 43.8B 4.58B 1.8B 22.92B 1.73B 1.7B 73.11B P/E 2027 *
-5.59x
P/E 2028 * -6.65x
Enterprise Value 596M 417M 372M 344M 312M 587M 39.55B 4.13B 1.62B 20.7B 1.57B 1.53B 66.03B EV / Sales 2027 *
-
EV / Sales 2028 * 17.4x
Free-Float
78.88%
Yield 2027 *
-
Yield 2028 * -
1 day-1.12%
1 week-7.81%
Current month-15.71%
1 month-18.81%
3 months-23.71%
6 months-43.45%
Current year-47.63%
1 week 1.68
Extreme 1.685
1.86
1 month 1.68
Extreme 1.685
2.23
Current year 1.68
Extreme 1.685
4.26
1 year 1.68
Extreme 1.685
5.2
3 years 0.98
Extreme 0.975
8.98
5 years 0.36
Extreme 0.36
8.98
10 years 0.36
Extreme 0.36
8.98
Manager TitleAgeSince
Chief Executive Officer - 11/10/2024
Chief Executive Officer - 01/01/2010
Director of Finance/CFO - 04/04/2022
Director TitleAgeSince
Chairman - 01/11/2013
Director/Board Member - 01/10/2010
Director/Board Member 72 29/03/2016
Date Insider Type Main position Quantity % Market Cap. Importance
4/22/26 A Sell

Chief Executive Officer

360,896 0.0969%
11/28/25 A Free

Chief Operating Officer

199,909 0.0537%
11/28/25 A Free

Chief Operating Officer

287,530 0.0773%
Change 5-day change 1-year change 3-year change Capi.($)
-1.12%-7.81%-63.73%+68.57% 466M
+0.79%-6.46%+52.86%+71.34% 65.83B
+1.92%+8.89%+12.90%+82.75% 51.87B
+6.91%+6.41%+9.61%+73.07% 51.2B
+0.74%+2.75%+26.31%+45.29% 43.76B
+3.87%+10.15%+20.69%+132.73% 42.09B
+7.91%+4.30%+263.91%+602.72% 39.04B
-0.40%+9.42%+18.44%+59.06% 34B
+3.84%-4.94%+42.35%+8.92% 25.2B
+2.36%+4.62%+24.20%+31.02% 22.8B
Average +2.70%-0.22%+40.75%+117.55% 37.63B
Weighted average by Cap. +3.07%+0.61%+50.98%+124.38%

Financials

2027 *2028 *
Net sales - 33.03M 23.13M 20.58M 19.08M 17.29M 32.49M 2.19B 229M 89.93M 1.15B 86.75M 84.95M 3.66B
Net income -121M -84.5M -75.21M -69.71M -63.17M -119M -8B -836M -329M -4.19B -317M -310M -13.36B -101M -70.76M -62.98M -58.37M -52.9M -99.41M -6.7B -700M -275M -3.51B -265M -260M -11.19B
Net Debt -64M -44.81M -39.88M -36.96M -33.49M -62.95M -4.24B -444M -174M -2.22B -168M -165M -7.09B -87M -60.91M -54.21M -50.24M -45.53M -85.57M -5.77B -603M -237M -3.02B -228M -224M -9.63B
Projected Income Statement - Annual - Clarity Pharmaceuticals Ltd
Logo Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing targeted copper theranostics based on its SAR Technology Platform. It is progressing clinical trials with its approximately three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. Its lead product, SAR-bisPSMA, is progressing through over three clinical trials: one theranostic trial (SECuRE) and two Phase III diagnostic trials (CLARIFY and AMPLIFY). SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2). SAR-bisPSMA is developed for diagnosing, staging, and treating prostate cancer that expresses prostate-specific membrane antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer.
Employees
100
Date Price Change Volume
20/10/26 A$1.770 -1.12% 2,633,283
19/10/26 A$1.790 -4.02% 2,500,931
16/10/26 A$1.865 +7.80% 2,659,299
15/10/26 A$1.730 -5.21% 3,225,369
14/10/26 A$1.825 +1.39% 2,794,306
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Clarity Pharmaceuticals Ltd
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.770AUD
Average target price
7.195AUD
Spread / Average Target
+306.50%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Clarity Pharmaceuticals Ltd